CymaBay Therapeutics Inc (USD)
CBAY
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range6.02 | 6.30
52-Wk Range- | -
Last Close6.09
Mkt Cap (m)419.52
Dividend yield-
ISINUS23257D1037
Volume667,261.00
Exchange VenueNAS

Company Profile

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

Key Information
Price/Earning-
Price/Book2.68
Price/Sales-
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 14/07/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.cymabay.com

Financials

Income Statement
USD201520162017201820192020
Revenue (m)0.000.0010.000.000.00-
Operating Income (m)-25.90-25.59-21.33-72.51-103.08-
Net Income (m)-15.53-26.67-27.56-72.55-102.81-
Basic EPS-0.82-1.14-0.79-1.25-1.53-
Avg. Diluted Shares Outstanding (m)18.9223.4534.9057.8467.03-
Balance Sheet
USD201520162017201820192020
Current Assets (m)42.7918.53103.54181.56202.92-
Non Current Assets (m)0.290.830.705.192.80-
Total Assets (m)43.0819.36104.25186.75205.73-
Current Liabilities (m)6.159.3116.3114.4217.64-
Total Liabilities (m)------
Total Equity (m)28.123.9484.95170.42186.35-
Cash Flows
USD201520162017201820192020
Operating Cash Flows (m)-23.32-23.35-19.63-54.94-97.91-
Capital Expenditure (m)--0.04-0.03-0.53-0.32-
Figures are quoted in USD unless stated otherwise
$
-
Last Price